XML 25 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Product revenues $ 2,689 $ 4,656
Cost of product revenues 1,318 2,170
Amortization of intangible assets 1,225 545
Gross profit 146 1,941
Development revenues:    
Government contracts and other 3,722 6,724
Total development revenues 3,722 6,724
Operating expenses:    
Research and development 11,678 16,197
Sales and marketing 3,593 3,611
General and administrative 7,594 8,563
Total operating expenses 24,551 28,371
Operating loss (20,683) (19,706)
Other income (expense):    
Interest income 33 19
Interest expense (2,049) (2,592)
Other income, net 13 233
Total other expense (2,003) (2,340)
Net loss (22,686) (22,046)
Beneficial conversion feature for convertible preferred stock (3,977) 0
Net loss allocable to common stockholders $ (26,663) $ (22,046)
Basic and diluted net loss per share allocable to common stockholders $ (0.82) $ (1.28)
Basic and diluted weighted average shares used in calculating net loss per share allocable to common stockholders 32,389,831 17,290,933
Comprehensive loss:    
Net loss $ (22,686) $ (22,046)
Other comprehensive income – foreign currency translation adjustments 129 262
Comprehensive loss (22,557) (21,784)
Azaya Therapeutics, Inc. [Member]    
Operating expenses:    
In process research and development acquired from Azaya $ 1,686 $ 0